Evidence mapPaperPMID 41131568Full record

ArticleLipids in health and disease2025

Evaluation of a new TyG indicator, TyHGB, in predicting non-alcoholic fatty liver disease: evidence from two independent populations.

Enfa Zhao, Ruimeng Wang, Yiqing Chen, Hang Xie, Yuan Gao, Bingtian Dong, Chaoxue Zhang

Abstract read
In one paragraph

Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Enfa ZhaoDepartment of Ultrasound, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Shushan District, Hefei, Anhui Province, 230022, China.
Ruimeng WangSecond Clinical Medical College, Anhui Medical University, Hefei, Anhui Province, 230022, China.
Yiqing ChenDepartment of Endocrinology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, 230022, China.
Hang XieDepartment of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China.
Yuan GaoDepartment of Ultrasound, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Shushan District, Hefei, Anhui Province, 230022, China.
Bingtian DongDepartment of Ultrasound, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Shushan District, Hefei, Anhui Province, 230022, China. dongbingtian@foxmail.com.
Chaoxue ZhangDepartment of Ultrasound, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Shushan District, Hefei, Anhui Province, 230022, China. zcxay@163.com.

Funding

Health Research Program of Anhui AHWJ2023A30169
6 · The paper itself

Abstract

backgroundAs non-alcoholic fatty liver disease (NAFLD) becomes increasingly common and affects population health, simple and effective screening tools for NAFLD are essential. The triglyceride high-density cholesterol-glucose body index (TyHGB), a novel metabolic index, has shown promise for predicting metabolic disorders. The objective of this research was to assess TyHGB's predictive capability for NAFLD across two distinct cohorts.

methodsThis retrospective study utilized data obtained from two independent cohorts: a Chinese hospital cohort (n = 181,241) and the National Health and Nutrition Examination Survey (NHANES) cohort (n = 3,286). TyHGB was computed according to the following equation: triglyceride level/high-density lipoprotein cholesterol level + 0.7 × fasting blood glucose level (mmol/L) + 0.1 × body mass index (kg/m²). NAFLD was diagnosed using ultrasonography. The TyHGB-NAFLD association was evaluated using multivariable logistic regression analysis, restricted cubic spline methodology, and receiver operating characteristic (ROC) curves. To establish the added predictive capacity of TyHGB over the triglyceride-glucose (TyG) index, net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were determined.

resultsIn both cohorts, participants with higher TyHGB values demonstrated a significantly higher prevalence of NAFLD. After full adjustment for potential confounders, the odds ratios for NAFLD on comparing the highest versus lowest quartiles of TyHGB were 12.22 (95% confidence interval [CI]: 10.73-13.93) in the Chinese cohort and 3.17 (95% CI: 2.25-4.46) in the NHANES cohort. Restricted cubic spline modeling demonstrated significant nonlinear associations between TyHGB values and NAFLD risk in both populations (P for nonlinearity < 0.001). TyHGB demonstrated superior discriminative ability for NAFLD in comparison with the TyG index, with area under the curve (AUC) values of 0.8410 versus 0.7995 in the Chinese cohort and 0.6492 versus 0.5952 in the NHANES cohort (both P < 0.001). Adding TyHGB to the baseline prediction models significantly improved risk discrimination, with greater improvements than those achieved by adding TyG (NRI: 0.0183, 95% CI: 0.015-0.0217; IDI: 0.0067, 95% CI: 0.0057-0.0076; both P < 0.001).

conclusionTyHGB demonstrated robust and superior performance in predicting NAFLD in comparison with the established TyG index across two diverse populations. Since TyHGB only requires routinely measured clinical parameters, it represents a practical and equitable tool for early NAFLD risk stratification across diverse healthcare settings, potentially reducing health disparities in liver disease detection and enabling cost-effective prevention strategies at the population level.

Indexed as

Blood GlucoseCholesterol, HDLNon-alcoholic Fatty Liver DiseaseTriglyceridesAdultBody Mass IndexChinaFemaleHumansMaleMiddle AgedNutrition SurveysRetrospective StudiesRisk FactorsROC CurveBlood GlucoseCholesterol, HDLTriglyceridesBMIInsulin resistanceNAFLDTriglyceride high-density cholesterol-glucose body indexTriglycerides

Identifiers

PMID41131568
PMCPMC12551267

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.